Eledon Pharmaceuticals (ELDN) Net Income towards Common Stockholders (2013 - 2026)
Eledon Pharmaceuticals (ELDN) posted Net Income towards Common Stockholders of -$21.3 million for Q1 2026, down 7.13% on a QoQ basis from -$19.9 million in Q3 2025, and down 254.68% year-over-year from $13.8 million in Q1 2025.
Eledon Pharmaceuticals (ELDN) Net Income towards Common Stockholders (2013 - 2026) Analysis & Trends
Eledon Pharmaceuticals' Net Income towards Common Stockholders history runs 14 years deep, the most recent figure standing at -$21.3 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 254.68% year-over-year to -$21.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$66.8 million (down 41.01% YoY) and the FY2025 annual result came in at -$42.3 million, down 32.31% from the prior year.
- Net Income towards Common Stockholders was -$21.3 million for Q1 2026 at Eledon Pharmaceuticals, down from -$19.9 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $6.7 million in Q3 2024 and bottomed at -$58.4 million in Q4 2022.
- A 5-year average of -$16.6 million and a median of -$11.4 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders sank 563.0% — and 2024, when it jumped 157.05%.
- Eledon Pharmaceuticals' Net Income towards Common Stockholders stood at -$58.4 million in 2022, then jumped by 82.12% to -$10.4 million in 2023, then slumped by 214.69% to -$32.8 million in 2024, then jumped by 39.52% to -$19.9 million in 2025, then fell by 7.13% to -$21.3 million in 2026.
- Business Quant data shows ELDN's Net Income towards Common Stockholders at -$21.3 million in Q1 2026, -$19.9 million in Q3 2025, and -$25.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Eledon Pharmaceuticals | 399.11 Mn | 399.11 Mn | - | -21.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.28 Mn |
| Sep 30, 2025 | -19.87 Mn |
| Jun 30, 2025 | -25.63 Mn |
| Mar 31, 2025 | -6.00 Mn |
| Dec 31, 2024 | -32.84 Mn |
| Sep 30, 2024 | 6.67 Mn |
| Jun 30, 2024 | -15.18 Mn |
| Mar 31, 2024 | -19.50 Mn |
| Dec 31, 2023 | -10.44 Mn |
| Sep 30, 2023 | -11.69 Mn |
| Jun 30, 2023 | -10.94 Mn |
| Mar 31, 2023 | -11.19 Mn |
| Dec 31, 2022 | -58.38 Mn |
| Sep 30, 2022 | -10.47 Mn |
| Jun 30, 2022 | -9.25 Mn |
| Mar 31, 2022 | -9.86 Mn |
| Dec 31, 2021 | -8.81 Mn |
| Sep 30, 2021 | -9.82 Mn |
| Jun 30, 2021 | -7.38 Mn |
| Mar 31, 2021 | -8.50 Mn |